Soc. Generale Knock-Out ABBV/ DE000SB0ZKL9 /
5/17/2024 9:45:04 PM | Chg.+0.150 | Bid9:59:30 PM | Ask9:59:30 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
8.370EUR | +1.82% | 8.400 Bid Size: 4,000 |
8.410 Ask Size: 4,000 |
AbbVie Inc | 75.126 USD | 12/31/2078 | Call |
GlobeNewswire
5/17
INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerev...
GlobeNewswire
5/16
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
GlobeNewswire
5/14
CEREVEL THERAPEUTICS HOLDINGS, INC. (NASDAQ: CERE) INVESTIGATION ALERT: Is $45 per CERE Share Enough...
GlobeNewswire
5/14
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
GlobeNewswire
5/14
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
5/14
In NCLA Amicus Win, and FTC Amicus Loss, Second Circuit Upholds Decision Dismissing Antitrust Suit
GlobeNewswire
5/9
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of...
GlobeNewswire
5/8
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...
GlobeNewswire
5/8
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
5/8
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...
GlobeNewswire
5/8
Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
GlobeNewswire
5/7
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
5/7
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update